, Psoriasis. Lancet, vol.386, pp.983-994, 2015.
Immunology of psoriasis, Annu. Rev. Immunol, vol.32, pp.227-255, 2014. ,
Immunopathogenesis of psoriasis, Exp. Dermatol, vol.16, pp.779-798, 2007. ,
Clinical improvement in psoriasis with specific targeting of interleukin-23, Nature, vol.521, pp.222-226, 2015. ,
,
, Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis, N. Engl. J. Med, vol.375, issue.2, pp.345-356, 2016.
Secukinumab in plaque psoriasisresults of two phase 3 trials, N. Engl. J. Med, vol.371, pp.326-338, 2014. ,
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N. Engl. J. Med, vol.373, pp.1318-1328, 2015. ,
IL-22 increases the innate immunity of tissues, Immunity, vol.21, pp.241-254, 2004. ,
The IL-20 subfamily of cytokinesfrom host defence to tissue homeostasis, Nat. Rev. Immunol, vol.14, pp.783-795, 2014. ,
Therapeutic opportunities of the IL-22-IL-22R1 system, Nat. Rev. Drug Discov, vol.13, pp.21-38, 2014. ,
Interleukin-22: immunobiology and pathology, Annu. Rev. Immunol, vol.33, pp.747-785, 2015. ,
IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes, J. Immunol, vol.174, pp.3695-3702, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-01705207
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis, Eur. J. Immunol, vol.36, pp.1309-1323, 2006. ,
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not, J. Mol. Med. (Berl.), vol.87, pp.523-536, 2009. ,
Integrative biology approach identifies cytokine targeting strategies for psoriasis, Sci. Transl. Med, vol.6, pp.223-245, 2014. ,
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation, J. Clin. Invest, vol.118, pp.597-607, 2008. ,
Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22, J. Immunol, vol.166, pp.7090-7095, 2001. ,
Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity, J. Immunol, vol.166, pp.7096-7103, 2001. ,
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist, Proc. Natl. Acad. Sci. USA, vol.98, pp.9511-9516, 2001. ,
A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta, Genes Immun, vol.2, pp.329-334, 2001. ,
Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid, Mucosal Immunol, vol.7, pp.101-113, 2014. ,
IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis, Mucosal Immunol, vol.9, pp.539-549, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02150949
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine, Nature, vol.491, pp.259-263, 2012. ,
Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function, Clin. Cancer Res, vol.20, pp.5507-5516, 2014. ,
IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis, Sci. Transl. Med, vol.5, pp.204-129, 2013. ,
Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa, J. Immunol, vol.186, pp.1228-1239, 2011. ,
RORgt+ cells selectively express redundant cation channels linked to the Golgi apparatus, Sci. Rep, vol.6, p.23682, 2016. ,
Induction of autoantibodies against mouse soluble proteins after immunization with living cells presenting the autoantigen at the cell surface in fusion with a human type 2 transmembrane protein, J. Immunol. Methods, vol.367, pp.56-62, 2011. ,
A role for T cell-derived interleukin 22 in psoriatic skin inflammation, Clin. Exp. Immunol, vol.150, pp.407-415, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-01705160
TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis, Eur. J. Immunol, vol.43, pp.3138-3146, 2013. ,
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis, J. Immunol, vol.182, pp.5836-5845, 2009. ,
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice, J. Immunol, vol.188, pp.462-469, 2012. ,
Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22, Immunity, vol.39, pp.372-385, 2013. ,
IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia, Nat. Med, vol.14, pp.275-281, 2008. ,
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis, Eur. J. Immunol, vol.39, pp.3570-3581, 2009. ,
Interregulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis, J. Invest. Dermatol, vol.131, pp.2428-2437, 2011. ,
Interleukin 20: discovery, receptor identification, and role in epidermal function, Cell, vol.104, pp.9-19, 2001. ,
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk, J. Clin. Invest, vol.122, pp.3965-3976, 2012. ,
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J. Exp. Med, vol.203, pp.2271-2279, 2006. ,
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol, J. Invest. Dermatol, vol.121, pp.1306-1311, 2003. ,
Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs, Exp. Dermatol, vol.15, pp.991-1004, 2006. ,
Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice, Immunity, vol.39, pp.899-911, 2013. ,
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis, J. Immunol, vol.178, pp.2229-2240, 2007. ,
IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression, Eur. J. Immunol, vol.39, pp.2779-2788, 2009. ,
Circulating Th17, Th22, and Th1 cells are increased in psoriasis, J. Invest. Dermatol, vol.130, pp.1373-1383, 2010. ,
Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions, Immunity, vol.43, pp.1040-1051, 2015. ,
IL-22 binding protein regulates murine skin inflammation, Exp. Dermatol, 2016. ,
Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart, Genes Immun, vol.5, pp.330-336, 2004. ,